Loading clinical trials...

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00504426

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.

Lead sponsor: Otsuka Pharmaceutical Co., Ltd.•5 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment101

Start dateJul 2007

Last updatedJan 30, 2014

Condition

Pain Due to Osteoporosis

Locations shown

Chubu Region

Hokkaido Region

Kanto Region

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 30, 2014Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions